Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives

Matthias F. Häfner a, b  Jürgen Debus a, b

a Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; b Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany

Introduction

Colorectal cancer (CRC) is one of the most commonly diagnosed malignant neoplasms worldwide, with an estimated 1.4 million occurrences and almost 700,000 deaths in 2012. Regions of high incidence are Northern America, Europe, and Australia/New Zealand [1]. In contrast to a mainly rising incidence rate over the last 20–30 years, specific mortality rates of CRC have decreased in a large number of countries, most likely due to screening examinations, prevention programs, and improved treatment options [1]. Advances in multimodal treatment strategies involving all major oncologic disciplines have contributed to a remarkably improved prognosis for affected patients. For rectal cancer in particular, radiotherapy has been established as a mainstay of treatment alongside surgery. In the present article, we review the role of radiotherapy in the management of CRC with a special focus on current treatment standards for locally advanced rectal cancer and provide an outlook on future challenges and approaches.

Neoadjuvant Radiotherapy

At the end of the 1980s and during the 1990s, evidence was growing that an addition of radiotherapy to exclusively surgical treatment of rectal cancer could improve patients’ prognosis. After the first prospective trials initiated in that phase had released their long-term results, a paradigm shift in the management of locally advanced rectal cancer took place towards multimodal treatment strategies.

The Swedish Rectal Cancer Trial was one of the first major studies in which a significant benefit of neoadjuvant irradiation compared to surgery alone [2] was found. By preoperatively applying a short-course radiotherapy (SC-RT) of 5 × 5 Gy, the overall survival (OS) was significantly improved from 30 to 38% (p = 0.008), and the local recurrence rate (LRR) decreased from 26 to 9% (p <
Radiotherapy for Colorectal Cancer

Vesc Med 2016;32:172–177

cases to preserve the sphincter muscle. Adjuvant chemoradiation should be avoided by thorough diagnostic work-up before treatment onset. Further, the management of proximal rectal cancer, i.e. 12–16 cm from the anal verge, is debated controversially due to the anatomical setting und the underrepresentation in the mentioned studies. A detailed overview of the relevant, major randomized trials for neoadjuvant SC-RT or LC-CRT is shown in table 1.

Toxicity

Besides the undisputed importance of acute toxicity in the evaluation of a treatment modality, late side effects of neoadjuvant radiotherapy in rectal cancer deserve special attention due to the functional sensitivity of concerned structures like the anal sphincter or the urinary tract. Long-term follow-up data from the Dutch trial [18] or Swedish cohorts [19] suggested high rates of fecal and urinary incontinence after SC-RT compared to surgery alone, thus impairing quality of life. However, from today’s perspective, old radiation techniques were used in these trials. More recent toxicity data from the British MRC CR07 trial also showed increased fecal incontinence rates associated with SC-RT; however, in most of the affected patients changes were reported on a low-grade level with rather minor impact on the quality of life [20].

Higher rates of acute toxicity are rather observed with LC-CRT than SC-RT, but incidence rates of late side effects do not show significant differences [11–14]. Gender-specific analyses of toxicity showed a significantly higher rate of hematologic and acute organ toxicity for female patients in the cohort of the German CAO/ARO/AIO-94 trial [21] and an increased rate of dyspareunia and vaginal dryness [22]. However, these data also resulted from outdated treatment application modes. Further, there was a slightly increased rate of sexual dysfunction compared to surgery alone in male patients treated with SC-RT; however, the main reason for sexual dysfunction was surgical morbidity[0] [20]. A recent pooled analysis of the Dutch trial [5] and the PORTEC trials for RT of endometrial cancer [23, 24] did not show an increased rate of secondary malignancies associated with RT [25]. However, there is no comparable analysis for combined CRT. Finally, neoadjuvant RT or CRT do not seem to deteriorate perioperative morbidity [26, 27].

Future Perspectives

Technical progress due to advanced radiation delivery techniques has found its way into the treatment of rectal cancer as well. Especially intensity-modulated radiotherapy (IMRT) has been broadly established in clinical use and has shown potential benefits with decreased toxicity for rectal cancer patients by reducing the radiation dose applied to the organs at risk [28, 29]. With particle irradiation (e.g. protons) even higher conformity of the therapeutic dose level and lower doses at healthy tissue seem possible, and the first planning studies have shown encouraging results [30]. On the

From a clinical point of view, SC-RT and LC-CRT are not competing but complementary strategies with a separate scope of use and partly different therapeutic goals: concordantly, both strategies aim to reduce the risk of local relapse. But as reflected in the major clinical guidelines [15–17], SC-RT is commonly recommended in early T3 stage without lymph node involvement, whereas LC-CRT is indicated for advanced T3 and T4 tumors with positive clinical circumferential resection margin (cCRM+) and/or positive lymph nodes to additionally downsize the tumor. The downsize effect aims at increasing the probability of R0 resection and in special
one hand, this development is expected to reduce rather high toxicity rates reported in the large, major trials mentioned above. On the other hand, a higher precision of the radiation beam also bears a higher risk of geographical miss of the target volume. Hence, advanced delivery techniques, especially particle RT, need further clinical validation.

Besides these technical aspects of dose delivery, the main future challenge for the management of rectal cancer is the identification of certain risk constellations that allow more differentiated and personalized treatment recommendations, especially for the highly debated heterogeneous group of stage II/III patients. Currently, two major approaches can be observed and are described in the following.

**Local De-Escalation**

After neoadjuvant RT has become a general recommendation for all stage II/III rectal cancer patients, the question emerged whether actually every patient of this group needs preoperative treatment, and, if not, how patients who probably will not benefit can be selected [31, 32]. Indeed, the introduction of TME lead to a significant improvement of local tumor control, and the OS advantage of neoadjuvant RT vanished. However, the addition of neoadjuvant RT to TME surgery reduces the risk of local relapse approximately by 50%, e.g. from 11 to 5% in the Dutch trial [5]. Estimated from that data, the number needed to treat in order to prevent one local relapse is approximately 20. The basic hypothesis for the identification of patients suitable for an exclusively surgical concept is that patients with negative nodal status, negative cCRM, and safe distance to the anal verge are unlikely to benefit from RT. So far, retrospective data suggest the permissibility of that approach, but at the same time they are too biased in terms of imbalanced collectives, short follow-up, and uncontrolled data to conclusively contribute to the question [26]. Further, very sensitive and specific diagnostic tools are necessary to prospectively select these patients. With an advanced thin slice protocol of magnetic resonance imaging (MRI), the MERCURY study group has developed a strong tool with a high prediction rate of pathological CRM status and a low rate of false-negative findings [33, 34]. However, the relevance of nodal status remains unclear. Further, there are findings from major studies that conflict with the hypothesis mentioned above and are not entirely understood until today. Whereas the entire cohort of the Dutch trial showed a better LRR with SC-RT without differences in OS, an OS benefit of 50 or 40% was found only in the subgroup of patients with negative CRM when SC-RT was applied or not [5]. The authors of the British MRC CR07 trial presented similar results [6] and additionally demonstrated that even patients with optimal TME significantly benefit from SC-RT in terms of LRR (1 vs. 7%) [35]. There are hints that a subgroup of patients does not require preoperative SC-RT or LC-CRT, but from today’s perspective reliable criteria to identify these patients are lacking.

The opposite question to that of local de-escalation is whether all patients undergoing neoadjuvant RT actually need surgery. For patients after LC-CRT, pathological complete remission (pCR) rates of 8–20% are reported [7, 11, 12, 36, 37]. These very good re-

---

**Table 1. Key trials for neoadjuvant RT of rectal cancer**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment</th>
<th>n</th>
<th>TME</th>
<th>FU</th>
<th>OS</th>
<th>LRR</th>
<th>pCR</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folkesson et al. [2]</td>
<td>i) SC-RT + surg ii) surg</td>
<td>908</td>
<td>no</td>
<td>156</td>
<td>13 years: 38%*</td>
<td>13 years: 9%*</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Swedish Rectal Cancer Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13 years: 38%*</td>
<td>13 years: 30%*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>van Gijn et al. [5]</td>
<td>i) SC-RT + surg ii) surg</td>
<td>1,861</td>
<td>yes</td>
<td>139</td>
<td>10 years: 49%</td>
<td>10 years: 5%*</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Dutch Rectal Cancer Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 years: 48%</td>
<td>10 years: 11%*</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Sebag-Montefiore et al. [6]</td>
<td>i) SC-RT + surg ii) surg + LC-CRT (CRM+)</td>
<td>1,350</td>
<td>(yes)</td>
<td>48</td>
<td>3 years: 51.5%</td>
<td>3 years: 10.6%*</td>
<td>n.d.</td>
<td>TME optional</td>
</tr>
<tr>
<td>MRC CR07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 years: 53.4%</td>
<td>3 years: 4.4%*</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Gérard et al. [9]</td>
<td>i) LC-CRT + surg ii) LC-RT + surg</td>
<td>733</td>
<td>(yes)</td>
<td>81</td>
<td>5 years: 67.4%</td>
<td>5 years: 8.1%*</td>
<td>11.4%*</td>
<td>TME recommended</td>
</tr>
<tr>
<td>FFCD 9203</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 years: 67.9%</td>
<td>5 years: 16.5%*</td>
<td>3.6%*</td>
<td></td>
</tr>
<tr>
<td>Sauer et al. [8]</td>
<td>i) LC-CRT + surg ii) surg + LC-CRT</td>
<td>799</td>
<td>yes</td>
<td>134</td>
<td>10 years: 59.6%</td>
<td>10 years: 7.1%*</td>
<td>8%</td>
<td></td>
</tr>
<tr>
<td>CAO/ARO/AIO-94</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 years: 59.9%</td>
<td>10 years: 10.1%</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>Buiko et al. [11]</td>
<td>i) SC-RT + surg ii) LC-CRT + surg</td>
<td>312</td>
<td>yes</td>
<td>48</td>
<td>4 years: 67.2%</td>
<td>4 years: 10.6%</td>
<td>0.7%*</td>
<td></td>
</tr>
<tr>
<td>Ngan et al. [12]</td>
<td>i) SC-RT + surg ii) LC-CRT + surg</td>
<td>326</td>
<td>(no)</td>
<td>71</td>
<td>5 years: 74%</td>
<td>5 years: 15.6%</td>
<td>16.1%*</td>
<td></td>
</tr>
<tr>
<td>TROG 01.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 years: 70%</td>
<td>3 years: 4.4%</td>
<td>1.5%*</td>
<td>(NHMRC GL 1999)</td>
</tr>
</tbody>
</table>

*aStatistically significant.

n = Patient number; TME = total mesorectal excision; FU = median follow-up; OS = overall survival; LRR = local relapse rate; pCR = pathological complete remission; SC-RT = short-course radiotherapy; surg = surgery; LC-CRT = long-course chemoradiotherapy (5-FU- or capecitabine-based); CRM+ = positive circumferential resection margin; n.d. = not done.
sponders might be eligible for a non-surgical approach. The first experiences with a wait-and-see policy instead of surgery in a smaller number of patients with clinical complete remission (cCR) showed encouraging results [38, 39]. Further, radiation and/or chemotherapeutic dose intensification beyond the usual LC-CRT regimen potentially increases the rate of cCR [40, 41]. Though salvage strategies seem basically feasible, a rather high 1-year LRR of 15–35% [40, 42] compared to the standard surgery-based approach is to be considered critically. Furthermore, the questions of optimal patient selection, adequate response assessment, and appropriate follow-up remain unanswered. So far, due to a lack of randomized evidence, organ-preserving treatment of rectal cancer is not recommended outside of clinical trials [43].

**Systemic Escalation**

The main debate in rectal cancer management predominantly dealt with local treatment strategies for a long time, but nowadays local control is excellent thanks to preoperative RT and TME. In contrast, overall survival rates are in need of improvement, and the major factor limiting the outcome is the appearance of metachronous distant metastases. The main approach to overcome this issue is the escalation of systemic therapy in the neoadjuvant setting, e.g. by addition of oxaliplatin to 5-FU- or capecitabine-based LC-CRT. Rödel et al. [41] demonstrated a significant improvement of the pCR rate (17 vs. 13%) and the 3-year disease-free survival rate (75.9 vs. 71.2%) with versus without oxaliplatin, in the absence of substantial increases in side effects; however, there was no improvement in OS. The standard use of oxaliplatin remains controversial though, especially when considering non-beneficial results from other trials with increased toxicity rates [36, 44]. For the subgroup of KRAS-wildtype patients, Dewdney et al. [45] have shown a benefit in OS by adding cetuximab to neoadjuvant treatment in a small cohort, but the primary objective of the study, i.e. a superior pCR rate, was missed. A short overview of remarkable trials with systemic escalation is given in table 2.

Future approaches include further treatment escalation, e.g. with induction chemotherapy prior to LC-CRT as examined in the currently recruiting German CAO/ARO/AIO-12 trial, as well as the identification of favorable subgroups by means of molecular parameters potentially offering new treatment targets.

**Special Situations**

**Oligometastases**

About 20 years ago, the definition of oligometastatic disease as an intermediate cancer stage between locally limited tumor spread and disseminated metastases was proposed by Hellman and Weichselbaum [46] and has increasingly been established in clinical practice ever since. The relevance of this concept including local treatment of an assumed systemic disease was demonstrated by some comprehensive works investigating the role of surgery for CRC liver metastases and showing 5-year OS rates of 25–47% [47–50]. Alternatively, less invasive locally ablative concepts such as radiofrequency ablation (RFA) or stereotactic body radiotherapy (SBRT) have emerged. Though large comparative trials are lacking, SBRT for liver metastases has shown beneficial results in CRC patients with 1-year local control rates of 56–100% [51]. Thus, SBRT is an excellent option for the local treatment of metastases with a good outcome and low toxicity rates, particularly for patients not suitable for surgery due to comorbidities or difficult technical resectability.

**Re-Irradiation**

In case of relapse, R0 resection is the most important prognostic marker. Hence, the use of surgery as radically as possible and

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment</th>
<th>n</th>
<th>TME</th>
<th>FU</th>
<th>OS</th>
<th>LRR</th>
<th>pCR, %</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aschele et al. [44]</td>
<td>LC-CRT (+ ox) + surg vs.</td>
<td>747</td>
<td>yes</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>16</td>
<td>response analysis</td>
</tr>
<tr>
<td>STAR-01</td>
<td>LC-CRT + surg</td>
<td>n.a.</td>
<td></td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>16</td>
<td>survival not published</td>
</tr>
<tr>
<td>Gérard et al. [36]</td>
<td>LC-CRT (+ ox) + surg vs.</td>
<td>598</td>
<td>yes</td>
<td>37</td>
<td>3 years: 87.6%</td>
<td>3 years: 4.4%</td>
<td>19.2</td>
<td></td>
</tr>
<tr>
<td>ACCORD 12/0405</td>
<td>LC-CRT + surg</td>
<td>n.a.</td>
<td></td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>13.9</td>
<td></td>
</tr>
<tr>
<td>PRODIGE 2</td>
<td></td>
<td>n.a.</td>
<td></td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rödel et al. [41]</td>
<td>LC-CRT (+ ox) + surg</td>
<td>1,236</td>
<td>yes</td>
<td>50</td>
<td>3 years: 88.7%</td>
<td>3 years: 2.9%</td>
<td>17%a</td>
<td></td>
</tr>
<tr>
<td>CAO/ARO/AIO-04</td>
<td>LC-CRT + surg</td>
<td>n.a.</td>
<td></td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>13%a</td>
<td></td>
</tr>
<tr>
<td>Dewdney et al. [45]</td>
<td>CHT + LC-CRT (+ ox + cet) + surg</td>
<td>90</td>
<td>yes</td>
<td>37</td>
<td>2 years: 91.3%</td>
<td>3 years: 2.2%</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>EXPERT-C</td>
<td>CHT + LC-CRT (+ ox) + surg</td>
<td>32</td>
<td></td>
<td>32</td>
<td>2 years: 81.8%</td>
<td>3 years: 4.5%</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

*aStatistically significant.

n = Patient number; TME = total mesorectal excision; FU = median follow-up; OS = overall survival; LRR = local relapse rate; pCR = pathological complete remission; ox = oxaliplatin; surg = surgery; cet = cetuximab; LC-CRT = long-course chemoradiotherapy (5-FU- or capecitabine-based); CHT = chemotherapy; n.a. = not applicable.
maintainable is the standard of care for locally recurrent rectal cancer. When safe resection with negative resection margins is questionable, a combination with neoadjuvant CRT is recommended in all patients that have not been treated with SC-RT or LC-CRT in first-line therapy. Nevertheless, also in patients with previous pelvic RT retreatment is useful under certain limitations. Recent analyses have demonstrated that re-irradiation positively influences resectability, resulting in a favorable OS [52]. On average, 30–40 Gy are applied in repeated RT depending on initial doses and elapsed time from initial treatment [53]. However, there is a huge variety of applied re-irradiation concepts including normofractionated external beam RT [54], hyperfractionated regimens [55], and intraoperative RT [56–59]. In patients re-irradiated within curative concepts, median OS is 39–60 months [53]. In patients in palliative settings, median OS is 12–16 months, and symptomatic relief, i.e. reduction of pain or tumor bleeding, can be achieved in the majority of cases [53, 54]. Acute toxicity seems acceptable with 9–20% (diarrhea), but the assessment of late side effects is difficult due to a lack of data so far [53]. Finally, particle RT with protons or heavy ions might allow further dose escalation in re-irradiation of rectal cancer without increasing toxicity, but clinical results in a larger number of patients are lacking [60, 61].

Conclusion

Radiotherapeutic concepts are crucial for the primary management of locally advanced rectal cancer and a helpful tool in the management of recurrent or oligometastatic CRC. Future research will have to focus on a better treatment selection for stage II/III patients in the primary setting and to find strategies to prevent prospective failure and improve long-term OS.

Disclosure Statement

The authors declare that they have no financial support or conflicts of interest pertaining to this report.

References


